Evidence map›Paper›PMID 32586284›Full record

ArticleBMC cancer2020

Opening large-conductance potassium channels selectively induced cell death of triple-negative breast cancer.

Gina Sizemore, Sarah McLaughlin, Mackenzie Newman, Kathleen Brundage, Amanda Ammer, Karen Martin, Elena Pugacheva, James Coad, Malcolm D Mattes, Han-Gang Yu

Abstract read
In one paragraph

Article in BMC cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed.

  1. Review
  2. Strategies for Targeting Mitochondria in the Treatment of Breast Cancer.ACS pharmacology & translational science · 2026
    Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. mitoBKeLife · 2024
    Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Gina SizemoreClinical and Translational Sciences Institute, West Virginia University, Morgantown, USA.
Sarah McLaughlinAnimal Models & Imaging Facility, Cancer Institute, West Virginia University, Morgantown, USA.
Mackenzie NewmanDepartment of Physiology & Pharmacology, West Virginia University, Morgantown, WV, 26506, USA.
Kathleen BrundageDepartment of Microbiology and Cell Biology, Flow Cytometry Facility, West Virginia University, Morgantown, USA.
Amanda AmmerAnimal Models & Imaging Facility, Cancer Institute, West Virginia University, Morgantown, USA.
Karen MartinAnimal Models & Imaging Facility, Cancer Institute, West Virginia University, Morgantown, USA.
Elena PugachevaDepartment of Biochemistry, Cancer Institute, West Virginia University, Morgantown, USA.
James CoadDepartment of Pathology, West Virginia University, Morgantown, USA.
Malcolm D MattesDepartment of Radiation Oncology, Cancer Institute, West Virginia University, Morgantown, USA.
Han-Gang YuDepartment of Physiology & Pharmacology, West Virginia University, Morgantown, WV, 26506, USA. hyu@hsc.wvu.edu.ORCID http://orcid.org/0000-0001-6838-8310

Funding

West Virginia IDEA-CTRU54GM104942 · NIGMS · WEST VIRGINIA UNIVERSITY · PI Sally Lynn Hodder · 2012 to 2026
$81.0M
WVU Flow Cytometry and Single Cell Core Facility (FCSCCF)P20GM121322 · NIGMS · WEST VIRGINIA UNIVERSITY · PI Dominique Bollino · 2018 to 2026
$22.4M
Stroke and Alzheimers Disease Related DementiasT32AG052375 · NIA · WEST VIRGINIA UNIVERSITY · PI Paul D Chantler, BERNARD G. SCHREURS · 2017 to 2026
$3.5M
The role of HEF1 protein in division and invasion of metastatic breast cancerR01CA148671 · NCI · WEST VIRGINIA UNIVERSITY · PI PUGACHEVA, ELENA NIKOLAEVNA · 2010 to 2020
$3.2M
Foundation for the National Institutes of Health U54GM104942NCI NIH HHS R01 CA148671NIA NIH HHS T32 AG052375NIGMS NIH HHS P20 GM121322NIGMS NIH HHS U54 GM104942
6 · The paper itself

Abstract

backgroundUnlike other breast cancer subtypes that may be treated with a variety of hormonal or targeted therapies, there is a need to identify new, effective targets for triple-negative breast cancer (TNBC). It has recently been recognized that membrane potential is depolarized in breast cancer cells. The primary objective of the study is to explore whether hyperpolarization induced by opening potassium channels may provide a new strategy for treatment of TNBC.

methodsBreast cancer datasets in cBioPortal for cancer genomics was used to search for ion channel gene expression. Immunoblots and immunohistochemistry were used for protein expression in culture cells and in the patient tissues. Electrophysiological patch clamp techniques were used to study properties of BK channels in culture cells. Flow cytometry and fluorescence microscope were used for cell viability and cell cycle studies. Ultrasound imaging was used to study xenograft in female NSG mice.

resultsIn large datasets of breast cancer patients, we identified a gene, KCNMA1 (encoding for a voltage- and calcium-dependent large-conductance potassium channel, called BK channel), overexpressed in triple-negative breast cancer patients. Although overexpressed, 99% of channels are closed in TNBC cells. Opening BK channels hyperpolarized membrane potential, which induced cell cycle arrest in G2 phase and apoptosis via caspase-3 activation. In a TNBC cell induced xenograft model, treatment with a BK channel opener significantly slowed tumor growth without cardiac toxicity.

conclusionsOur results support the idea that hyperpolarization induced by opening BK channel in TNBC cells can become a new strategy for development of a targeted therapy in TNBC.

Indexed as

AnimalsApoptosisBreastCaspase 3Cell Line, TumorDatasets as TopicFemaleG2 Phase Cell Cycle CheckpointsHumansIntravital MicroscopyLarge-Conductance Calcium-Activated Potassium Channel alpha SubunitsMembrane PotentialsMiceOxadiazolesPatch-Clamp TechniquesTetrazoles1-(3,5-bis(trifluoromethyl)phenyl)-3-(4-bromo-2-(1H-tetrazol-5-yl)phenyl)thiourea3-((5-chloro-2-hydroxyphenyl)methyl)-5-(4-(trifluoromethyl)phenyl)-1,3,4-oxadiazol-2(3H)-oneCASP3 protein, humanCaspase 3KCNMA1 protein, humanLarge-Conductance Calcium-Activated Potassium Channel alpha SubunitsOxadiazolesTetrazolesThioureaHyperpolarizationPotassium channelsTriple-negative breast cancer

Identifiers

PMID32586284
PMCPMC7318490

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.